ChemoID test results correlated with patients’ OS and PFS
tumor, death
TUMOR
Survival and PFS of each patient in the planned interim efficacy analysis were also analyzed as a function of the cell kill of the patient’s cultured tumor cells (both CSCs and bulk tumor cells) in response to the drug(s) used during treatment (Our analysis further revealed that for every 10% increase in CSC drug response, there was a significant increase (13%) in 6-month patient survival (HR, 0.87; p = 0.012), and for every 10% increase in bulk tumor cell response, the hazard of death decreased 13% (HR, 0.87; p = 0.024). We also found that for every 10% increase in cell kill, the hazard of progression at 6 months decreased by 14% for CSCs (HR, 0.86; p = 0.005) and 18% for bulk tumor cells (HR, 0.82; p = 0.001).For survival trials, HR is the standard reporting mechanism; however, restricted mean survival time (RMST) is also a robust method for assessing the treatment effect.In our exploratory studies, we also analyzed the cohort of patients with rGBM by removing subjects affected by The trial allowed the optional inclusion of BV during treatment because it has been shown in large trials and meta-analyses that BV treatment in combination with chemotherapy improves the management of symptoms and quality of life in patients with rGBM but not the OS.